QuatRx Pharmaceuticals Co.
This article was originally published in Start Up
Executive Summary
Built to order for its Big Pharma veteran founders, QuatRx Pharmaceuticals is in-licensing and developing novel therapies for cardiovascular, endocrine, and metabolic disorders. Its growing pipeline includes two lipid drugs licensed from Ilex Oncology Inc.
You may also be interested in...
Deltanoid Pharmaceuticals Inc.
The University of Wisconsin - Madison spin-off is modifying the vitamin D molecule to enhance its bone building activity for the treatment of osteoporosis.
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain Therapeutics
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.